Boundless Bio
Boundless Bio's Overview
Boundless Bio is a clinical-stage biopharmaceutical company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to develop transformative therapies for patients with oncogene amplified cancers. They are focused on pioneering a new paradigm in cancer therapeutics by designing and developing ecDNA-directed therapeutics (ecDTx) to eradicate cancer cells that rely on ecDNA for growth, resistance, and recurrence. The company leverages its Spyglass platform to identify and validate ecDNA-dependent targets and develop ecDTx.
Where is Boundless Bio's Headquarters?
HQ Function
Primary center for research and development, clinical operations, and corporate administration, focusing on discovering and advancing ecDNA-targeted cancer therapies.
Notable Features:
State-of-the-art laboratory facilities and collaborative office workspaces designed to foster innovation in oncology research. Located within a prominent life sciences campus with access to modern amenities.
Work Culture:
A dynamic, science-driven, and collaborative environment focused on tackling challenging cancer biology. Emphasizes innovation, rigor, urgency, teamwork, and a commitment to developing transformative medicines for patients.
HQ Significance:
Strategically located in San Diego, one of the largest and most active life science clusters in the world, providing access to a rich talent pool, leading research institutions, and a supportive biotech ecosystem.
Values Reflected in HQ: The headquarters reflects Boundless Bio's commitment to cutting-edge science, collaboration, and efficiency, designed to accelerate the development of novel cancer therapies for patients with high unmet medical needs.
Location:
While headquartered in the United States, Boundless Bio's clinical trials and research collaborations may extend globally to advance its ecDNA-targeted therapies. The company aims to address oncogene amplified cancers, a worldwide health challenge, and may partner with international institutions and Contract Research Organizations (CROs) to support its drug development programs and reach patients globally.
Street Address:
9880 Campus Point Drive, Suite 120
City:
San Diego
State/Province:
California
Country:
USA
Boundless Bio's Global Presence
Buying Intent Signals for Boundless Bio
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Executive Team of Boundless Bio
As of April 2025, Boundless Bio' leadership includes:
Investors of Boundless Bio
Boundless Bio has been backed by several prominent investors over the years, including:
Executive New Hires/Exits in the Last 12 Months
Boundless Bio strategically strengthened its executive team in the past year, notably with the appointment of a new Chief Financial Officer in mid-2023, aligning with its growth trajectory and successful IPO in March 2024. The core leadership team has otherwise shown stability with no major publicized departures.
New Appointments:
Technology (Tech Stack) used by Boundless Bio
Discover the tools Boundless Bio uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Boundless Bio Email Formats and Examples
Boundless Bio likely utilizes common corporate email address patterns. A frequently observed format in biotech companies is the first initial followed by the last name.
flast@boundlessbio.com
Format
jdoe@boundlessbio.com
Example
75%
Success rate
News and media
Boundless Bio / GlobeNewswire • April 8, 2024
Boundless Bio Presents New Preclinical Data on Novel ecDNA Manufacturing Hub Inhibitor Program at AACR Annual Meeting 2024
Boundless Bio presented new preclinical data from its ecDNA manufacturing hub inhibitor (EMHI) program, featuring its development candidate BBI-355, at the American Association for Cancer Research (AACR) Annual Meeting 2024. The data highlighted BBI-355's potential in treating oncogene-amplified cancers by disrupting ecDNA replication and repair mechanisms....more
Boundless Bio / GlobeNewswire • March 28, 2024
Boundless Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Boundless Bio announced the closing of its upsized initial public offering of 7,812,500 shares of its common stock, including the full exercise of the underwriters' option to purchase an additional 1,012,500 shares, at a public offering price of $16.00 per share. The aggregate gross proceeds from the offering were approximately $125.0 million, before deducting underwriting discounts and commissions and other offering expenses....more
Boundless Bio / GlobeNewswire • January 4, 2024
Boundless Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of BBI-825, a First-in-Class Oral Inhibitor of CHK1 for Patients with Oncogene Amplified Cancers
Boundless Bio announced that the first patient has been dosed in its first-in-human Phase 1/2 clinical trial of BBI-825. BBI-825 is an orally available, selective inhibitor of Checkpoint Kinase 1 (CHK1) being evaluated in patients with locally advanced or metastatic cancer with oncogene amplifications....more
Highperformr’s free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including Boundless Bio, are just a search away.